TRIAL DETAIL

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Drug:
Trial Name:
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 08/01/2011
Age of Trial (yrs) 12.7
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor + MEK inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CMEK162X2101, EudraCT 2011-001083-22
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals 800-340-6843
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Singapore
Singapore
55 Fruit Street
Boston
MA
02114
USA
Detroit
MI
48201
USA
1275 York Ave
New York
NY
10065
USA
Greenville
SC
29615
USA
Hufelandstr. 55
Essen
45122
Germany
Heidelberglaan 100
Utrecht
3584 CX
Netherlands
119-129
Barcelona
08035
Spain